Announced study outcomes from its proprietary multi-analyte check DecisionDx-EC today.

Â.. Castle Biosciences reports research results from DecisionDx-EC multi-analyte test for esophageal cancer Castle Biosciences Inc. Announced study outcomes from its proprietary multi-analyte check DecisionDx-EC today, which is made to determine which sufferers with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy. The results were examined in a poster display at the 50th Annual Interacting with of the American Culture of Clinical Oncology .Cykiert’s complete report, view the video in the participant above.

CLC bio, PSSC Labs announce new turnkey solution for full-genome analysis and assembly Today, CLC bio and PSSC Labs announced a new turnkey solution, CLC Genomics Factory, for assembly, read mapping, and subsequent downstream evaluation of very large amounts of high-throughput DNA and RNA sequencing data. Built mainly because a high-performance bioinformatics appliance, CLC Genomics Factory will come in three different sizes with varying numbers of compute nodes, capable of processing the data output from up to 10 Illumina HiSeq2000 or 7 Life Technologies Sound 4 systems.